Vivus Calls First Manhattan’s Board Change A Serious Threat

VIVUS, Inc. (NASDAQ:VVUS) today sent a letter to its shareholders indicating First Manhattan Co’s campaign to replace Vivus’ existing board a serious threat. The pharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health in its today’s letter to the shareholders, emphasized that there is no shortcut to unlock the value represented by Qsymia. Qsymia Seen Slow Pick Up Once touted as a promising therapy to fight a U.S. obesity epidemic, doctors have been slow to pick it up given the troubled past of obesity drugs. Qsymia’s side effects include heart risks and the possibility…